First time 10-year prospective outcome data confirms clinical utility of Read More
ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative Read More
IRVINE, CA and AMSTERDAM – 6 July 2017 - Agendia, Read More
Retrospective analysis of patient samples from the prospective, randomized Stockholm Read More
A multi-center trial demonstrated that MammaPrint identified 30% more low Read More
Agreement Accelerates the Development of Tests to Help Assess Risk Read More
IRVINE, CA and AMSTERDAM – 1 June 2017 – Agendia, Read More
IRVINE, CA and AMSTERDAM – 2 May 2017 – Agendia, Read More
IRVINE, CA and AMSTERDAM – 12 April 2017 – Agendia, Read More
MammaPrint® is the first and only multigene test to receive Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
